MedTrace Logo

Latanoprost Versus Fotil

NCT00304785 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2007-10-24

No results posted yet for this study

Summary

To compare the intraocular pressure effect and safety of latanoprost 0.005% given every evening versus PTFC given twice daily.

Conditions

Interventions

DRUG

latanoprost 0.005%

DRUG

Fotil

DRUG

placebo

Sponsors & Collaborators

  • Pharmaceutical Research Network

    lead OTHER

Principal Investigators

  • William C. Stewart, MD · Pharmaceutical Research Network, LLC

  • Józef Kałużny, Professor · Gabinety Okulistyczne

  • Krystyna Pecold, Professor · Kierownik Kliniki Okulistycznej Akademii Medycznej

  • Roman Sobecki, Dr. n.med. · Ordynator Oddziału Okulistycznego Międzyleski Szpital Specjalistyczny

  • Krystyna Czechowisz-Janicka, Professor · Instytut Jaskry

  • Dariusz Kecik, Professor · Katdra Klinika Okulityki Akademii Medycznej w Warszawie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2007-10-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304785 on ClinicalTrials.gov